/
Cardiovascular
Angina Pectoris
12
Pipeline Programs↗
3
Active Trials↗
13
Companies Involved↗
Angina Pectoris is an emerging landscape with 12 programs across 13 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical12
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
11 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
32
clinical trials
Unknown status13 · 41%
Completed13 · 41%
Recruiting2 · 6%
Withdrawn2 · 6%
Active, not recruiting1 · 3%
Terminated1 · 3%
Clinical Trials
Trial Activity
32 trials
Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death
Recruiting·—·Approved·NCT02845531·140 enrolled
Acupoint Application in Patients With Stable Angina Pectoris (AASAP)
Completed·—·Phase 1·NCT02029118·200 enrolled
Acupuncture in Patients With Stable Angina Pectoris
Completed·—·N/A·NCT01686230·404 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)